Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CEO Jennifer L. Good sold 4,219 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $3.03, for a total value of $12,783.57. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares of the company's stock, valued at $646,338.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Trevi Therapeutics Stock Up 5.8 %
Shares of TRVI opened at $3.12 on Tuesday. The company has a 50-day moving average price of $2.87 and a two-hundred day moving average price of $2.87. The stock has a market cap of $219.76 million, a price-to-earnings ratio of -9.18 and a beta of 0.96. Trevi Therapeutics, Inc. has a 12 month low of $0.97 and a 12 month high of $4.00.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same period last year, the company posted ($0.07) earnings per share. Equities research analysts expect that Trevi Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.
Wall Street Analyst Weigh In
War on Elon Escalates…
From Porter & Company | Ad
Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades.
By doing so he has put himself in the crosshairs of an ideological war with the global elites.
And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
Click here to learn how you can benefit from its widespread distribution.
Several research firms recently commented on TRVI. Rodman & Renshaw started coverage on shares of Trevi Therapeutics in a research note on Thursday, June 13th. They set a "buy" rating and a $7.00 target price for the company. Raymond James started coverage on shares of Trevi Therapeutics in a research report on Friday, August 30th. They set an "outperform" rating and a $9.00 price objective for the company. EF Hutton Acquisition Co. I raised Trevi Therapeutics to a "strong-buy" rating in a research report on Monday, August 19th. HC Wainwright started coverage on Trevi Therapeutics in a report on Friday, August 30th. They issued a "buy" rating and a $6.00 price target for the company. Finally, Leerink Partners started coverage on Trevi Therapeutics in a research report on Monday. They issued an "outperform" rating and a $7.00 price objective for the company. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Trevi Therapeutics has an average rating of "Buy" and a consensus target price of $7.67.
Get Our Latest Research Report on Trevi Therapeutics
Institutional Investors Weigh In On Trevi Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the company. Frazier Life Sciences Management L.P. increased its position in shares of Trevi Therapeutics by 7.3% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 7,381,090 shares of the company's stock worth $9,891,000 after purchasing an additional 500,000 shares in the last quarter. Logos Global Management LP increased its holdings in shares of Trevi Therapeutics by 27.3% during the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company's stock worth $8,344,000 after buying an additional 600,000 shares in the last quarter. Opaleye Management Inc. raised its stake in shares of Trevi Therapeutics by 4.3% in the first quarter. Opaleye Management Inc. now owns 2,645,000 shares of the company's stock valued at $9,125,000 after acquiring an additional 110,000 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Trevi Therapeutics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company's stock worth $7,948,000 after acquiring an additional 60,249 shares in the last quarter. Finally, Ally Bridge Group NY LLC bought a new stake in Trevi Therapeutics during the 2nd quarter worth approximately $4,395,000. Institutional investors and hedge funds own 95.76% of the company's stock.
About Trevi Therapeutics
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
